PEG showed no clear difference in serious adverse events compared with lactulose (low certainty).
PEG showed no clear difference in successful disimpaction compared with milk of magnesia (MOM) (low certainty).
Certolizumab pegol 200 mg sc (with or without MTX) probably leads to lower all Withdrawals: All doses of certolizumab pegol vs placebo compared with placebo (with or without MTX) (moderate certainty).
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).
Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).
It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).
Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).